Mercado global de anemia hemolítica adquirida (autoimune) – Tendências do setor e previsão para 2029

Análise e dimensão do mercado                              

A anemia hemolítica é um tipo de anemia que ocorre quando os glóbulos vermelhos se decompõem ou morrem mais rapidamente do que o organismo consegue substituí-los por novos. A anemia hemolítica pode ser causada pela herança de doenças genéticas causadoras de anemia, infeções ou medicamentos específicos. O tratamento da anemia hemolítica varia de acordo com a origem da doença. As transfusões de sangue, os medicamentos corticosteróides e o rituximab são tratamentos possíveis. A cirurgia para remoção do baço é recomendada em casos mais graves. A anemia hemolítica por anticorpos quentes e a anemia hemolítica por anticorpos frios são dois tipos de anemia hemolítica adquirida (autoimune). Os autoanticorpos ligam-se aos glóbulos vermelhos na anemia hemolítica por anticorpos quentes e destroem-nos a uma temperatura superior à temperatura corporal; na anemia hemolítica por anticorpos ao frio, os anticorpos autogerados matam os glóbulos vermelhos a uma temperatura inferior à temperatura corporal.

A Data Bridge Market Research analisa que o mercado da anemia hemolítica adquirida (autoimune) foi avaliado em 676,75 milhões de dólares em 2021 e deverá atingir os 992,28 milhões de dólares até 2029, registando um CAGR de 4,90% durante o período de previsão de 2022 a 2029. Além disso aos insights de mercado, tais como valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes do mercado e cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito do relatório e segmentação de mercado

Definição de mercado

A anemia hemolítica adquirida não genética (autoimune) surge quando o próprio sistema imunitário do organismo elimina os tecidos saudáveis ​​em resposta a organismos invasores, como os linfócitos e os anticorpos. O tratamento centra-se em três objetivos principais: prevenir a destruição dos glóbulos vermelhos, aumentar a contagem de glóbulos vermelhos e tratar a doença subjacente. As principais opções de tratamento incluem transfusões de sangue, medicamentos, plasmaférese e procedimentos. Para tratar a anemia hemolítica adquirida (autoimune), são habitualmente utilizados medicamentos como a prednisona, rituximab, hidroxiureia e ciclosporina.

Dinâmica do mercado da anemia hemolítica adquirida (autoimune)

Motoristas

• Aumento da prevalência de anemia por deficiência de ferro

Estima-se que a crescente prevalência da anemia por deficiência de ferro influencie a taxa de crescimento do mercado. Juntamente com isto, as crescentes incidências de doenças autoimunes, como o lúpus, a artrite reumatoide , a síndrome de Sjogren, as doenças da tiroide, a doença de Hashimoto e a colite ulcerosa influenciarão a dinâmica do mercado durante o período de previsão.

• Aumentar o investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado da anemia hemolítica adquirida (autoimune) é o aumento dos gastos em saúde, o que ajuda a melhorar as suas infraestruturas. Além disso, várias organizações governamentais pretendem melhorar a infra-estrutura de cuidados de saúde através do aumento do financiamento, o que influenciará ainda mais a dinâmica do mercado.

• Número crescente da população geriátrica

The increasing number of geriatric population is estimated to enhance the market's growth rate. According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. The proportion of the geriatric population is estimated to rise. The elderly population is more prone to acquired (autoimmune) hemolytic anemia, further enhancing the market's growth rate. Acquired (autoimmune) hemolytic anemia can affect people of all ages and genders, though it most commonly occurs in females over the age of 40.

Furthermore, a surging number of government initiatives to spread awareness and sedentary lifestyle will result in the expansion of acquired (autoimmune) hemolytic anemia market. Along with this, rising level of disposable income and increase in the risk of haemodilution will enhance the market's growth rate.

Opportunities

• Rise in R&D activities  

The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.

Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of the acquired (autoimmune) hemolytic anemia market during 2022-2029. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the acquired (autoimmune) hemolytic anemia market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the market's growth rate during the forecast period of 2022-2029.

This acquired (autoimmune) hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acquired (autoimmune) hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Autoimmune hemolytic anemia is rare, affecting approximately 1 to 2 of every 100,000 people yearly.

The acquired (autoimmune) hemolytic anemia market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some data variables available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

COVID-19 Impact on Acquired (Autoimmune) Hemolytic Anemia Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for various reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of acquired (autoimmune) hemolytic anemia in recent months.

Recent Development

• In February 2022, The U.S. Food and Drug Administration (FDA) announced the approval of Enjaymo (sutimlimab-jome). It decreases red blood cell transfusion requirement due to hemolysis in adults with cold agglutinin disease (CAD). Enjaymo is the first as well as only approved treatment for people with CAD and functions by inhibiting the destruction of red blood cells (hemolysis).

Global Acquired (Autoimmune) Hemolytic Anemia Market Scope

The acquired (autoimmune) hemolytic anemia market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Warm Autoimmune Induced Hemolytic Anemia
• Cold Agglutinin Disease (CAD)
• Others

Treatment

• Medication
• Corticosteroids
• Immunosuppressive agents
• Others
• Blood Transfusion
• Surgery
• Splenectomy
• Others

Diagnosis

• Blood Tests
• Coombs Test
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acquired (Autoimmune) Hemolytic Anemia Market Regional Analysis/Insights

The acquired (autoimmune) hemolytic anemia market is analyzed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the acquired (autoimmune) hemolytic anemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America and Europe dominate the acquired (autoimmune) hemolytic anemia market because of the well-established healthcare infrastructure in this region. Additionally, the growing focus of major key players on novel technology will further propel the market's growth rate in this region.

Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the growing number of patient populations and the large number of generic manufacturers in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Acquired (Autoimmune) Hemolytic Anemia Market Share Analysis

The acquired (autoimmune) hemolytic anemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acquired (autoimmune) hemolytic anemia market.

Some of the major players operating in the acquired (autoimmune) hemolytic anemia market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Fresenius SE & Co. KGaA (Germany)
• Lupin (India)
• ViforPharma Ltd. (Switzerland)
• AMAG Pharmaceuticals (U.S.)
• Akebia Therapeutics, INC.
• CHO-A Farmacêutico CO., LTD. (Coreia do Sul)
• Orion Corporation (Finlândia)
• Pharmacosmos A/S (Dinamarca)
• Shield Therapeutics (Reino Unido)
• Advanz Farmacêutica (Reino Unido)
• Laboratórios Alkem (Índia)
• Zydus Cadila (Índia)
• Hikma Pharmaceuticals PLC (Reino Unido)

SKU-53441